Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : URMD -- Huge market potential -- Ignore unavailable to you. Want to Upgrade?

To: Hugh A. McWhorter who wrote (200)	1/27/1998 12:23:00 AM
From: Rick Riebesell	Read Replies (1) \| Respond to of 369

From the 10Q of URMD for quarter ended September 30, 1997: "The company believes that available cash, cash equivalents and short term investments will be sufficient to meet the Company's operating expenses and capital requirements for the foreseeable future. The Company's future liquidity and capital requirements depend on numerous factors, including, but not limited to, development of the Company's marketing capability, market acceptance of the Reliance Insert, the Impress Softpatch, the INTROL Bladder Neck Support Prosthesis and the BEACON Technology system surgical line, the uncertainty of widespread medical reimbursement, development of the Company's manufacturing capability and achieving acceptable cost of production, the uncertain protection afforded the company by its intellectual property rights and/or patents relating to the Reliance Insert, the Impress Softpatch and the INTROL Bladder Neck Support Prosthesis, the development status of other potential products, including but not limited to the BreastCheck device, the BreastExam device and the CaverMap surgical aid, potential acquisitions and other potential strategic product opportunities. There can be no assurance that the Company will not require additional financing or that, if required, such financing will be available on terms acceptable to the Company." Also from the 10Q: " . . . The Company anticipates increased sales and marketing expenditures in the fourth quarter of 1997 and the first quarter of 1998 due to increased costs in connection with conducting the Impress Softpatch test market and preparation for the U.S. launch of the Impress Softpatch in early 1998, increased costs in connection with marketing and sales efforts of the BEACON Technology surgical line, and as a result of internal development activities including the BreastCheck breast self examination device, the physician-use BreastExam device, and the CaverMap Surgical Aid." The 10Q does not project increased earnings occurring before June 1998. The prospects for increased earnings in 1998 depend on the degree of market acceptance of the company's products. While there are a variety of products, it is difficult to project a sure winner from the information we now have. Rick